ArticleBMC cancer2025
The interdisciplinary management of craniopharyngioma - practice patterns, outcomes, and insights.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCraniopharyngiomas are rare, mostly benign brain tumors, and their management remains challenging due to the limited data from large cohorts. This study evaluates the practice patterns and outcomes for craniopharyngioma patients managed at a tertiary care center.
methodsThis retrospective cohort study included patients with histologically confirmed craniopharyngioma treated between 1996 and 2022. Patient, tumor, and treatment variables were analyzed for their association with local control (LC), progression-free survival (PFS), and overall survival (OS) using multivariable Cox regression models.
resultsA total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 62.0 and 42.5 months, respectively. Fifty-three recurrences and twelve deaths were observed. After primary treatment, the 2-, 4, and 6-year LC and PFS rates were 69.1, 50.7, 37.7% and 71.5, 55.4, and 47.3%, respectively. For patients undergoing primary treatment, multivariable Cox regression showed an association between the extent of resection, i.e., gross total resection (GTR), and PFS (hazard ratio (HR): 0.36, p = 0.01) with weaker evidence for LC (HR: 0.40, p = 0.053). Age was the only variable associated with OS (HR: 1.05, p = 0.01). Seventeen patients received radiotherapy, which was not formally associated with LC, PFS, and OS. The majority of patients required hormone replacement therapy after treatment.
conclusionsThis study underlines the role of GTR in delaying disease progression and the need for hormone replacement after treatment. While radiotherapy was not formally associated with any benefit in this series, its use might be helpful in candidates after subtotal resection and for treating recurrences. Further prospective research is needed to refine treatment algorithms, improve long-term outcomes, and optimize the quality of life of affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.